AFM
DMAC icon

Anson Funds Management’s DiaMedica Therapeutics DMAC Stock Holding History

Anson Funds Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-130,070
Closed -$485K – 372
2021
Q4 		$485K Buy
+130,070
New +$511K 0.05% 250

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Anson Funds Management's DMAC Position: Q1 2022 in Review

Anson Funds Management sold out of DiaMedica Therapeutics (DMAC) in Q1 2022, closing a stake of 130,070 shares — an estimated $485K sold.

Anson Funds Management first reported a position in DMAC in Q4 2021 and held it in 1 quarter. The position peaked at $485K in Q4 2021. 34 funds tracked by Wall St. Rank hold DMAC as of Q1 2022.

  • Anson Funds Management reported no remaining DiaMedica Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 130,070 DiaMedica Therapeutics shares in Q1 2022, an estimated $485K.
  • Anson Funds Management first reported a position in DiaMedica Therapeutics in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's DiaMedica Therapeutics position peaked at $485K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.